Tandem Diabetes Care (TNDM) EBITDA Margin (2013 - 2026)
Tandem Diabetes Care's (TNDM) quarterly EBITDA Margin came in at 5.42% in Q2 2026, up 1611.0% on a YoY basis from 0.32% in Q2 2025, and up 23.17% quarter-over-quarter from 7.05% in Q1 2026.
Powered by 
Analysis
Tandem Diabetes Care (TNDM) EBITDA Margin (2013 - 2026) Analysis & Trends
Tandem Diabetes Care (TNDM) has reported EBITDA Margin for 14 consecutive years, with 5.42% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin rose 1611.0% year-over-year to 5.42%; the trailing twelve-month figure through Jun 2026 stood at 4.4% (up 1550.0% YoY), and the FY2025 full-year result was 18.45%, down 791.0% from the prior year.
- EBITDA Margin climbed to 5.42% in Q2 2026 per TNDM's latest filing, from 7.05% in the prior quarter.
- Across five years, EBITDA Margin topped out at 2.86% in Q4 2025 and bottomed at 75.46% in Q1 2023.
- Historically, EBITDA Margin has averaged 17.48% across 5 years, with a median of 12.28% in 2024.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin slumped 6674 bps in 2023, then soared 5372 bps in 2024.
- Over 5 years, EBITDA Margin stood at 8.06% in 2022, then sank by 121 bps to 17.82% in 2023, then jumped by 99 bps to 0.21% in 2024, then jumped by 1490 bps to 2.86% in 2025, then tumbled by 290 bps to 5.42% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 5.42%, 7.05%, and 2.86% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 13.44% |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 33.60% |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 18.08% |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 25.18% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 21.65% |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 29.48% |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 0.40% |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 24.33% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 19.15% |
| 10 | Tandem Diabetes Care | 1.26 Bn | 804.14 Mn | 144.78 Mn | -5.42% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.42% |
| Mar 31, 2026 | -7.05% |
| Dec 31, 2025 | 2.86% |
| Sep 30, 2025 | -9.17% |
| Jun 30, 2025 | -21.53% |
| Mar 31, 2025 | -51.56% |
| Dec 31, 2024 | -0.21% |
| Sep 30, 2024 | -10.70% |
| Jun 30, 2024 | -13.87% |
| Mar 31, 2024 | -21.74% |
| Dec 31, 2023 | -17.82% |
| Sep 30, 2023 | -16.99% |
| Jun 30, 2023 | -19.81% |
| Mar 31, 2023 | -75.46% |
| Dec 31, 2022 | -8.06% |
| Sep 30, 2022 | -23.22% |
| Jun 30, 2022 | -6.11% |
| Mar 31, 2022 | -8.72% |
| Dec 31, 2021 | 6.07% |
| Sep 30, 2021 | 4.30% |